Refractory MCL: CD19-, CD20-Targeting CAR T-Cell Therapy Has Encouraging Initial Trial Results

0 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
At the Medical College of Wisconsin, Nirav Shah, MD, MSHP, is an associate professor of medicine in the Hematology and Oncology Division. He is also director of the Bone Marrow Transplant and Cellular Therapy Program at the College.

Dr. Shah spoke with Blood Cancers Today about the single-center phase I/II clinical trial he led to evaluate treatment of relapsed or refractory mantle cell lymphoma (MCL) with LV20.19, a lentiviral chimeric antigen receptor (CAR) T-cell therapy that targets both CD19 and CD20. His team published the findings in Journal of Clinical Oncology.

In the phase I portion of the trial, the team assessed the safety of LV20.19 and also tested a shortened manufacturing process for this agent. They followed this with a phase II arm, which included patients with treatment-resistant MCL, and sought to optimize administration of this agent.

“The median [number of] lines of treatment for this patient population was actually four, demonstrating that they were quite refractory patients that had seen lots of other therapies. Every single patient was BTK inhibitor exposed, and about half the patients actually had a p53 aberration,” Dr. Shah elaborated.

The trial team was impressed with the agent’s efficacy results. Dr. Shah reported that the overall response rate was 100% and that only two patients in the cohort of 17 had experienced relapse at the time of the study’s publication. The agent also had a favorable safety profile.

“There were no patients with high-grade cytokine release syndrome, so grade 3 to 4, and there were low rates of grade 3 or higher neurotoxicity events. In fact, there were just two patients in the cohort that had only grade 3 neurotoxicity, both of which were reversible with treatment,” Dr. Shah explained.

Regarding next steps following these promising initial study findings, Dr. Shah said a larger multicenter phase II clinical trial of LV20.19 in relapsed or refractory MCL is currently enrolling in the US.
------------
Blood Cancers Today is a new publication that provides hematologists and oncologists with news, education, and information relevant to their patients and practices, with insight from experts in the field. As the online home of the publication, bloodcancerstoday.com is updated daily, with the most current information from around the specialty and multimedia content, including exclusive interviews with presenters at major medical meetings.

Blood Cancers Today was developed to reach all professionals in the hematology/oncology universe, covering the latest news and analysis in leukemia, lymphoma, myeloma, myeloproliferative neoplasms, and other hematologic malignancies.
Category
Oncology
Be the first to comment

Up Next